Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

Joshua J Neumiller
Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, WA, USA

Citation

Copyright
© 2014 Neumiller JJ. This is an open-access article distributed under the terms of the Creative Commons Attribution License Deed CC BY NC ND 3.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No other uses without permission.

Correct attribution
Copyright © 2014 Neumiller JJ. Published by Drugs in Context under Creative Commons Attribution License Deed CC BY NC ND 3.0. http://dx.doi.org/10.7573/dic.212262

Article URL

Correspondence
Joshua J Neumiller. Assistant Professor, Department of Pharmacotherapy, College of Pharmacy, Washington State University, PO Box 1495, Spokane, WA 99218, USA. jneumiller@wsu.edu

Provenance
Submitted, externally peer reviewed

Dates
Submitted: 4 March 2014
Accepted, subject to peer review: 5 March 2014
Revised manuscript submitted: 28 May 2014
Published: 11 June 2014

Publisher & contact information
Drugs in Context is published by Just Medical Media Ltd, 1 Redgrove Park, Cheltenham, Gloucestershire GL51 6QY, UK; ISSN 1740-4398; Just Medical Media Limited is registered in England Number 6891187; VAT GB 945 1713 22
Julia Savory
Head of Digital Publishing and Submissions Management julia@justmedicalmedia.com; Tel: +44 (0)1242 910 999

Abbreviations
AE, adverse event; bid, twice daily; CI, confidence interval; CKD, chronic kidney disease; CV, cardiovascular; DPP-4, dipeptidyl-peptidase-4; eGFR, estimated glomerular filtration rate; EMA, European Medicines Agency; FDA, Food and Drug Administration; FDC, fixed-dose combination; FPG, fasting plasma glucose; GLP-1, glucagon-like peptide 1; GLUT, glucose transporter; HbA1c, glycosylated hemoglobin; MI, myocardial infarction; OAD, oral antidiabetes drug; OGGT, oral glucose tolerance test; PPG, post-prandial glucose; qd, once daily; SBP, systolic blood pressure; SD, standard deviation; SE, standard error; SGLT1/2, sodium-glucose co-transporters; UGE, urinary glucose excretion; ZDF, Zucker diabetic fatty (rat).
Drugs in Context • www.drugsincontext.com
ISSN: 1740 - 4398

ENDOCRINOLOGY EDITORIAL BOARD

Specialist Editor-in-Chief
Professor Eva M Vivian, PharmD
Associate Professor, University of Wisconsin-Madison School of Pharmacy, Madison, WI, USA

Specialist Health Economics Editor
Dr Won Chan Lee, PhD
Principal, Health Economics and Outcomes Research, IMS Consulting Group, Alexandria, VA, USA

Specialist Advisor – Epidemiology
Professor Jennifer Robinson, MD
Clinical Assistant Professor, Department of Pharmacotherapy, Washington State University College of Pharmacy, Spokane, WA, USA

Specialist editorial board members
Marlon E Cerf, MD
Specialist Scientist, Diabetes Discovery Platform, South African Medical Research Council, South Africa
Pamela Daniels, MBA, MPH, PhD
Epidemiologist, Morehouse School of Medicine, 720 Westview Drive, SW, MRC Annex S-10, Atlanta, GA, USA
Professor Stuart T Haines, PharmD
Professor and Vice Chair for Clinical Services, Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD, USA; Clinical Pharmacy Specialist, West Palm Beach VA Medical Center, West Palm Beach, FL, USA
Sivaramakrishna Koganti, PhD
Department of Internal Medicine, Carver College of Medicine, University of Iowa, USA
Professor Elena Quattrochi, PharmD
Associate Professor, Division of Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Staten Island University Hospital, NY, USA
Evan Sisson, PharmD, MHA, CDE
Virginia Commonwealth University, School of Pharmacy, Virginia, USA
Junhua Yu
Assistant Professor, Social, Behavioral and Administrative Sciences, Touro University College of Pharmacy, Vallejo, CA, USA

Group Editor-in-Chief
Christopher Blanchette, PhD, MBA
Associate Dean for Research and Research Associate Professor in the Department of Public Health Sciences at the University of North Carolina and Director of Health Economics & Outcomes Research at Otsuka America Pharmaceutical Inc, USA

Expert Advisers – Epidemiology and biostatistics
Alex K Exuzides, PhD
Director, ICON Clinical Research Inc, California, USA
Professor Scott L Friedman, MD
Fishberg Professor of Medicine, Dean for Therapeutic Discovery Chief, Division of Liver Diseases, Mount Sinai School of Medicine, New York, USA
Carl De Moor, PhD
Senior Principal, Epidemiology and Leader Epidemiology, Safety and Risk Management Center of Excellence Americas, IMS Health Inc, USA
Dr John H Walker, OCT, MBA, PhD
Professor, Goodman School of Business, Brock University, St Catharines, Ontario, Canada

Expert Adviser – Publication Ethics
Dr Elizabeth (Liz) Wager
Publications Consultant, Princes Risborough, UK; Visiting Professor, University of Split School of Medicine, Croatia; Former Chair (2009-2012), Committee on Publication Ethics (COPE)

Editor-in-Chief Emeritus
Dr George Kassianos, FRCGP, FESC, FBGTHA, FAcadMEd, FFTM RCPSGlasc
General Practitioner, Bracknell, Berkshire, UK; President British Global & Travel Health Association Fellow of the European Society of Cardiology

Specialist Advisor – Clinical Pharmacology
Dr Richard White, MA, PhD
Consulting Partner and Director, Oxford PharmaGenesis Ltd, UK

To see the full Drugs in Context Editorial Board, please visit www.drugsincontext.com/editorial-board

ENDOCRINOLOGY
Introduction

In patients with type 2 diabetes, higher levels of hyperglycemia are associated with increasing risk of vascular events, with each 1% increase in glycosylated hemoglobin (HbA1c) associated with as much as 38% increased risk of mortality [1]. In patients with type 1 diabetes, intensive diabetes therapy has been clearly shown to reduce the incidence of clinical cardiovascular events including myocardial infarction, stroke, and cardiac death. In type 2 diabetes, the relationship between therapeutic reduction of HbA1c and mortality risk has not been so clearly demonstrated, but good glycemic control undoubtedly reduces the risk of microvascular outcomes such as retinopathy, neuropathy, and nephropathy, with possible long-term effects on cardiovascular outcomes such as myocardial infarction [2–4]. Effective glycemic control is therefore considered central to patient management, and a number of glucose-lowering therapies are available. Yet in clinical practice many patients do not achieve glycemic goals [5]. The most frequently cited reason is the side-effect profiles of available agents, in particular hypoglycemia and weight gain, although unwillingness to begin insulin injections may also play a role [6,7]. Furthermore, many patients do not maintain individualized glycemic goals, due to the natural progression of type 2 diabetes [8]. Novel anti-hyperglycemic therapies are therefore intensively sought, with recent success in the area of promoting glucose excretion [9]. Until recently, preventing urinary glucose excretion (UGE) was thought a measure of diabetes control, but this shift to considering UGE as a therapeutic strategy has led to the development of a whole new class of drugs for glucose

Citation


Abstract

Type 2 diabetes is increasing in prevalence worldwide, and hyperglycemia is often poorly controlled despite a number of therapeutic options. Unlike previously available agents, sodium-glucose co-transporter 2 (SGLT2) inhibitors offer an insulin-independent mechanism for improving blood glucose levels, since they promote urinary glucose excretion (UGE) by inhibiting glucose reabsorption in the kidney. In addition to glucose control, SGLT2 inhibitors are associated with weight loss and blood pressure reductions, and do not increase the risk of hypoglycemia.

Empagliflozin is a selective inhibitor of SGLT2, providing dose-dependent UGE increases in healthy volunteers, with up to 90 g of glucose excreted per day. It can be administered orally, and studies of people with renal or hepatic impairment indicated empagliflozin needed no dose adjustment based on pharmacokinetics. In Phase II trials in patients with type 2 diabetes, empagliflozin provided improvements in glycosylated hemoglobin (HbA1c) and other measures of glycemic control when given as monotherapy or add-on to metformin, as well as reductions in weight and systolic blood pressure. As add-on to basal insulin, empagliflozin not only improved HbA1c levels but also reduced insulin doses. Across studies, empagliflozin was generally well tolerated with a similar rate of hypoglycemia to placebo; however, patients had a slightly increased frequency of genitourinary infections, but not urinary tract infections, versus placebo. Phase III studies have also reported a good safety profile along with significant improvements in HbA1c, weight and blood pressure, with no increased risk of hypoglycemia versus placebo. Based on available data, it appears that empagliflozin may be a useful option in a range of patients; however, clinical decisions will be better informed by the results of ongoing studies, in particular, a large cardiovascular outcome study (EMPA-REG OUTCOME™).

Keywords: Blood glucose, combination drug therapy, empagliflozin, hemoglobin A1c protein, hypertension, obesity, sodium-glucose co-transporter 2 (SGLT2) inhibitors, type 2 diabetes
control; namely, the sodium-glucose co-transporter 2 (SGLT2) inhibitors or ‘gliflozins’ which promote UGE by inhibiting glucose reabsorption in the kidney [9]. This review considers the mechanism of gliflozins, before reviewing the available evidence for a gliflozin currently in late-stage development, empagliflozin.

Glucose reabsorption in healthy people

The kidneys are crucial for maintaining glucose homeostasis, and contribute to this process via glucose uptake, gluconeogenesis, and reabsorption of glucose from the glomerular filtrate into the circulation [10,11]. On average, an individual’s entire blood volume is filtered by the kidney more than 50 times daily, with around 160–180 g of glucose filtered from plasma by glomeruli every day (180 L per day at approximately 100 mg/dL of glucose) [12]. Under normal circumstances, this filtered glucose is almost completely reabsorbed in the proximal tubules of the kidney, leaving the urine free of glucose.

The reabsorption of filtered glucose is mediated by SGLTs, a family of active, sodium-dependent, large trans-membrane proteins [13]. Two members of the SGLT family are involved in glucose reabsorption in the kidney: SGLT2 is a high-capacity, low-affinity transporter, expressed in the early convoluted segment of the proximal tubule, and has traditionally been thought to be responsible for nearly 90% of the active renal glucose reabsorption [14–17]; while SGLT1, a high-affinity, low-capacity transporter, expressed in the distal segment of the proximal tubule, reabsorbs the remaining 10% (Figure 1) [14,17]. SGLT2 is thought to be expressed exclusively in renal proximal tubules, but SGLT1 is also found in the gastrointestinal tract, where it is responsible for absorption of galactose as well as glucose [15,18]. For both SGLTs, glucose reabsorbed from the proximal tubules by SGLTs is then passively diffused into the circulation via facilitative glucose transporters (GLUTs) at the basolateral membrane of the cells lining the proximal tubule [11].

Glucose reabsorption in people with type 2 diabetes

In patients with type 2 diabetes, blood glucose levels eventually become so high that they exceed the capacity of the SGLT2 transporters, at a threshold of approximately 200 mg/dL (11.0 mmol/L) [19]. Thus, not all glucose is reabsorbed, and glucose begins to appear in the urine. Unfortunately, in patients with ongoing hyperglycemia, up-regulation of glucose transporter genes increases the level of renal glucose reabsorption [20]. This increased threshold for glucose transport minimizes UGE and intensifies hyperglycemia [10,19,21]; however, once this increased threshold is exceeded, the characteristic glucosuria is detected.

In recent years, realistic options for promoting UGE via SGLT inhibition have been identified. Efforts have focused on selective SGLT2 inhibition, as this transporter is expressed almost exclusively in renal proximal tubules and its inhibition is therefore unlikely to affect other organ systems [18]. Individuals who lack functional SGLT1 have severe gastrointestinal symptoms due to malabsorption of glucose and galactose [22], while people who lack a functional gene for SGLT2 generally lead normal healthy lives, despite the presence of higher-than-normal levels of glucose in their urine [23]. In people lacking SGLT2 (a condition known as familial renal glycosuria), essential levels of glucose are maintained, and although SGLT2 normally transports around 90% of the 180 g of glucose reabsorbed, inhibition of SGLT2 typically only results in maximum excretion of about 50% (90 g) of glucose, suggesting that when SGLT2 is inhibited, SGLT1 capacity can be increased [12]. Besides reduction in blood glucose, SGLT2 inhibition has the additional potential advantages of weight loss (corresponding to the calories lost daily in excreted glucose) as well as no increase in hypoglycemia (since insulin secretion is not stimulated) when used as monotherapy.

Phlorizin, a compound originally isolated from the bark of apple trees, was the first SGLT inhibitor identified. Despite
its ability to induce glucosuria, phlorizin was not clinically developed because it had low bioavailability, degraded rapidly after oral administration to phloretin (a potent inhibitor of GLUT transporters), and inhibited SGLT1 (with consequent gastrointestinal side effects) [24,25]. It nevertheless provided a structural foundation for the development of other compounds with greater bioavailability following oral administration and higher selectivity for SGLT2. The structure of phlorizin consists of a glucose ring and two aromatic rings joined by a glycosidic oxygen [26]. Analogs containing O-glucoside were initially developed; however, these compounds were still susceptible to hydrolysis by glucosidases in the intestine. C-glucosides proved more metabolically robust, and the glucose-based SGLT2 inhibitors currently in various phases of clinical development all use a C-aryl linkage [27]. A number of compounds have reached Phase III clinical trials: two (canagliflozin and dapagliflozin) have been approved for use in type 2 diabetes by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA). A third SGLT2 inhibitor, empagliflozin, was approved for use in type 2 diabetes by the EMA in May 2014, and an application to the FDA is pending. Thus, this is a useful time to review the early therapeutic studies of the empagliflozin clinical development program, focusing on the mechanism of action and dose-ranging studies, as well as the trials that are currently ongoing.

Empagliflozin in preclinical studies

The chemical compound BI 10773 that was developed by Boehringer Ingelheim Pharmaceuticals (Ingelheim, Germany) and later named empagliflozin (pronounced em" pa gli floe' zin) [28], uses a C-glucoside-based structure. In vitro, empagliflozin has been shown to be a potent and highly specific SGLT2 inhibitor, with >2500-fold selectivity towards SGLT2 (IC$_{50}$ 3.1 nM) in comparison with SGLT1 (IC$_{50}$ 8300 nM) [29], which suggests that the renal pharmacologic response would be solely mediated by SGLT2 [27]. In comparison, IC$_{50}$ values for canagliflozin are 2.7 nM for SGLT2 and 710 nM for SGLT1, while IC$_{50}$ values for dapagliflozin are 1.2 nM (SGLT2) and 1400 nM (SGLT1), for which a transient effect on SGLT1 may be predicted while the compound is at very high concentration due to oral absorption. In a tracer study in 20 healthy people, canagliflozin appeared to reduce the rate of oral glucose absorption, which the investigators thought likely to be due to intestinal SGLT1 inhibition, but this requires further investigation [30].

In animal model studies using Zucker diabetic fatty (ZDF) rats, single doses of empagliflozin of 1 or 3 mg/kg or vehicle (placebo) resulted in dose-dependent increases in UGE, and 5 weeks of treatment with 0.3, 1, or 3 mg/kg empagliflozin or vehicle reduced levels of fasting plasma glucose (FPG) and HbA1c, and improved glucose tolerance in response to glucose challenge [31]. During the study, there was no sign of hypoglycemia, and insulin sensitivity was also increased [31]. In an 8-week study in ZDF rats, empagliflozin 3 mg/kg once-daily provided sustained glycemic responses and also showed improvement in beta-cell mass, raising the possibility that empagliflozin could preserve pancreatic function [32]. In dietary-induced obese rats, empagliflozin resulted in a significant increase in UGE as well as significant weight losses after 4 weeks (4.1% of body weight with empagliflozin 3 mg/kg once-daily and 6.9% with 10 mg/kg, both significant versus placebo) [33]. There were no changes in body water or protein content, confirming loss of fat accounted for the majority of the observed weight loss. These preclinical data indicated that empagliflozin showed promise for the treatment of type 2 diabetes in humans, and clinical investigations ensued, following the standardized phases of a clinical development program.

Pharmacokinetic, pharmacodynamics, safety, and drug–drug interaction studies

An initial study of empagliflozin was designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single escalating doses of empagliflozin in 72 healthy male volunteers [34]. Subjects were recruited at a single center in Germany: eight subjects were randomized to each dose of empagliflozin (0.5, 2.5, 10, 25, 50, 100, 200, 400 or 800 mg), and within each dose two subjects received placebo in a double-blinded fashion. Participants in the 50-mg group also took part in an oral glucose tolerance test (OGTT). Pharmacokinetic analyses showed empagliflozin was rapidly absorbed after oral administration, with a median t$_{max}$ ranging from 1.5 to 2.1 hours across the dose groups. Plasma levels declined in a biphasic fashion with a rapid distribution phase and a slower elimination phase. Exposure to empagliflozin was approximately dose-proportional over the range of 0.5–800 mg. The terminal elimination half-life was up to 13.1 hours, and renal clearance over 72 hours ranged from 32.1 mL/min to 51.3 mL/min. The majority of empagliflozin was excreted via the urine in the first 24 hours, with approximately 11–19% of the administered dose excreted unchanged.

All doses of empagliflozin inhibited reabsorption of glucose in the urine, with empagliflozin doses up to 10 mg inhibiting reabsorption of up to 40% of filtered glucose, while higher doses inhibited reabsorption of 40–60% of filtered glucose (translating to a maximum of 90 g of glucose). The total amount of glucose excreted over 72 hours increased with dose, reaching a plateau at around the 100 mg empagliflozin dose. As expected in healthy people, plasma glucose levels were similar among participants treated with any dose of empagliflozin or placebo (since the liver compensates by increasing glucose production to prevent hypoglycemia), and in the OGTT, 75 g of glucose had no relevant effects on the pharmacokinetics of empagliflozin. The number of subjects experiencing an adverse event (AE) was similar for the empagliflozin and placebo groups, and no safety concerns were identified.
A Phase I study with a similar design was used to investigate dose–response relationships in 48 healthy Japanese men [35]. Again, eight subjects were randomized to each empagliflozin dose tested (1, 5, 10, 25, and 100 mg, with a second group receiving 10 mg with an OGTT). As in the Caucasian subjects, empagliflozin was well tolerated with dose-proportional exposure, and showed increased UGE with increasing drug dose. Exposure was approximately 1.5-fold higher, which the study investigators thought likely due to the differences in body weights between the populations (the median body weight was 20% lower in the Japanese volunteers than in the German group). It appeared, however, that the exposure did not affect levels of UGE, with similar levels at corresponding empagliflozin doses, establishing that the same therapeutic dose could be used in this population.

The effect of food on the bioavailability of empagliflozin absorption was investigated in an open-label, randomized, cross-over study in 14 healthy male volunteers [34]. Subjects received 50 mg empagliflozin after an overnight fast of at least 10 hours or immediately after consumption of a high-fat, high-calorie meal. There were no differences in AE profiles when empagliflozin was given with or without food, and food produced no clinically relevant effects on drug exposure, indicating that empagliflozin is suitable for once-daily administration independent of meal timing.

Patients with type 2 diabetes are frequently prescribed multiple medications to achieve glycemic, blood pressure, lipid, and other individualized treatment goals [36]. Accordingly, empagliflozin has been tested in combination with other drugs commonly used in people with type 2 diabetes, including other glucose-lowering agents (metformin [37], sitagliptin [38], linagliptin [39], glimepiride [40]), an anticoagulant (warfarin [41]), cardiovascular/antihypertensive medicines (the diuretics hydrochlorothiazide or torasemide [42], verapamil, ramipril, digoxin [43]), and a cholesterol-lowering agent (simvastatin [44]). These drug–drug interaction studies were all open-label, cross-over trials performed in healthy volunteers, apart from the investigation with diuretics, which was carried out in patients with type 2 diabetes. Furthermore, as oral contraceptives may be co-administered with antidiabetes agents, the interaction of empagliflozin with a combined oral contraceptive was also investigated in healthy female volunteers [45]. No clinically relevant effects occurred following co-administration of empagliflozin with any of the above-listed medications, and it was concluded that empagliflozin may be co-administered with these medications without the need for dosage adjustments. A randomized, double-blind, placebo-controlled study in 30 healthy volunteers also showed that neither a single therapeutic dose of empagliflozin (25 mg) nor a supratherapeutic dose (200 mg) were associated with prolongation of cardiac repolarization (as measured by the QT interval) or heart rate [46]. Again, empagliflozin doses were well tolerated in these subjects.

Following these successful studies in healthy volunteers, trials were designed to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of empagliflozin in patients with type 2 diabetes. A randomized, double-blind, placebo-controlled study investigated multiple escalating doses of empagliflozin (2.5 mg to 100 mg once daily) over 8 days in patients with type 2 diabetes [47]. A total of 48 patients were randomized to one of four doses of empagliflozin (2.5, 10, 25, or 100 mg once daily) or placebo; in each group, nine patients received active drug and three received placebo. Empagliflozin was well tolerated with approximately dose-proportional exposure and resulted in clinically meaningful increases in UGE, ranging from 77.9 mg after a single dose of empagliflozin 10 mg, to 89.8 g with empagliflozin 100 mg. These results were consistent with those of a similar study, also in patients with type 2 diabetes but with a 4-week duration, in which 78 patients were randomized to empagliflozin 10, 25, or 100 mg or placebo [48]. The patients also had an OGTT at the start and end of the study. By Day 1, UGE increased with empagliflozin treatment (74 g in the 10-mg group, 90 g in the 25-mg group and 81 g in the 100-mg group, compared with no significant change in the placebo group), and increased UGE was maintained throughout the study. Significant improvements in FPG were also observed and in post-OGTT blood glucose levels compared with the start of the study. Empagliflozin was well tolerated in this study, with similar proportions of patients in empagliflozin and placebo groups experiencing AEs. These results were further supported by a 4-week study of empagliflozin in Japanese patients with type 2 diabetes, in which 100 patients were randomized to receive 1, 5, 10, or 25 mg of empagliflozin, or placebo, once daily [49]. After 4 weeks, all empagliflozin groups showed significant increases in UGE (40.8 g, 77.1 g, 80.9 g, and 93.0 g versus –2.1 g for placebo), and empagliflozin was well tolerated.

A significant proportion of patients with type 2 diabetes have renal impairment, and as renal function can affect drug pharmacokinetics and pharmacodynamics, a single dose of empagliflozin (50 mg) was tested in an open-label, parallel-group study conducted at two European centers [50]. Forty subjects were recruited: a control group of eight subjects with type 2 diabetes and mild renal impairment (eGFR >90 mL/min/1.73 m²); nine subjects with type 2 diabetes and mild renal impairment (eGFR 60–89 mL/min/1.73 m²); seven with type 2 diabetes and moderate renal impairment (eGFR 30–59 mL/min/1.73 m²); eight with severe renal impairment (eGFR <30 mL/min/1.73 m²), four of whom also had type 2 diabetes, and eight subjects with renal failure/end-stage renal disease requiring dialysis (none of whom had type 2 diabetes). Pharmacokinetic properties of empagliflozin were largely unaltered by renal impairment, suggesting that no dose adjustments are required in patients with renal impairment. As expected, exposure to empagliflozin increased moderately with increasing renal impairment, thought to be due to decreased clearance of empagliflozin.
This decreased clearance could offset the reduced protein binding in patients with renal impairment, suggesting clinically meaningful reductions in plasma glucose levels could be expected with empagliflozin even in patients with moderate renal impairment.

The effect of hepatic impairment on the pharmacokinetics, safety, and tolerability of empagliflozin has also been studied in an open-label trial [51]. Volunteers with varying degrees of hepatic impairment (but not with type 2 diabetes) were enrolled (eight each with mild, moderate, or severe hepatic impairment and 12 matched controls with normal hepatic function); all were given a single dose of empagliflozin 50 mg, double the maximum planned therapeutic dose. In the patients with hepatic impairment, increases in empagliflozin exposure were less than 2-fold exposure in those with normal hepatic function, and the drug was well tolerated, indicating that it can also be used without dose adjustment in this population.

**Phase II studies (safety data and further exploratory efficacy data)**

In the Phase I studies described above, empagliflozin was well tolerated and appeared promising in terms of glucose improvements and thus was entered into Phase II trials, including three studies of 12-week duration, and two longer-term studies.

To assess empagliflozin as monotherapy, a Phase II, randomized, double-blind, placebo-controlled trial evaluated the efficacy, safety, tolerability, and pharmacokinetics of empagliflozin (5, 10, and 25 mg once daily) in patients with type 2 diabetes over 12 weeks [52]. As well as a placebo control arm, the study also included an open-label metformin arm (1000 mg twice-daily, or maximum tolerated dose). Steady-state concentrations of empagliflozin were maintained throughout the 12-week duration of the study, and increased in proportion to dose. By 12 weeks, empagliflozin induced a dose-dependent and statistically significant reduction in HbA1c compared with placebo (Table 1). Furthermore, the decreases in FPG and HbA1c that occurred with 25 mg empagliflozin appeared similar to those obtained with the maximum tolerated dose of metformin [52]. The mean weight loss in the three empagliflozin groups ranged between 1.8 and 2.3 kg (Table 1), and the agent was well tolerated, with no reports of hypoglycemia (Table 2).

Metformin is currently recommended as the first-line treatment for patients with type 2 diabetes, thus, in clinical practice, empagliflozin would likely be used as an add-on therapy to metformin. Consequently, the safety and efficacy of empagliflozin (1, 5, 10, 25, and 50 mg once daily) has also been investigated in patients with type 2 diabetes who were inadequately controlled on metformin [53]. A Phase II, randomized, double-blind, placebo-controlled study was conducted – also 12 weeks in duration and including an open-label sitagliptin 100 mg once daily arm. When compared with placebo, all empagliflozin doses except 1 mg showed significant and dose-dependent reductions in HbA1c and body weight (Table 1). Empagliflozin was generally well tolerated with a slightly increased frequency of genital infections, but not urinary tract infections, when compared with placebo (Table 2).

Furthermore, a pooled analysis of data (10 mg and 25 mg dose groups) from these two Phase II studies assessed blood pressure changes from baseline after 12 weeks of treatment [54]. Systolic blood pressure (SBP) decreased by 4–5 mmHg with empagliflozin, and the change was significant versus placebo for each dose group. The changes appeared to be greater among patients with SBP >140 mmHg at baseline. Diastolic blood pressure changes were not statistically significant when compared with placebo.

Patients from the preceding two studies also participated in an open-label extension study for an additional 78 weeks [55]. Patients randomized to 1, 5, or 50 mg of empagliflozin or placebo in the preceding trial were re-randomized to 10 or 25 mg empagliflozin, while those previously randomized to 10 mg or 25 mg empagliflozin, metformin, or sitagliptin continued with the same treatment. Patients who did not switch at the start of the extension study therefore had a total of 90 weeks on continuous treatment. These patients had sustained reductions in HbA1c, FPG, and weight. Of all patients in the 78-week extension (including ‘switching’ as well as ‘continuing’ patients), AEs were reported at a similar rate across groups, and the majority were mild or moderate. Hypoglycemic events were reported in 0.9–2.4% of patients on empagliflozin, 3.6% on metformin monotherapy, and 3.6% on sitagliptin add-on to metformin. Adverse events related to urinary tract infections were reported in 3.8–12.7% of patients on empagliflozin, 3.6% on metformin, and 12.5% on sitagliptin, and AEs related to genital infections were reported in 3.0–5.5% of patients on empagliflozin, 1.8% on metformin, and none on sitagliptin.

The long-term efficacy and safety of empagliflozin has also been investigated as add-on therapy to basal insulin [56]. Patients with type 2 diabetes were randomized to empagliflozin 10 mg or 25 mg once daily or placebo; the basal insulin regimen was kept constant for the first 18 weeks, after which the treating investigator could adjust the regimen at their discretion for the following 60 weeks. As well as significant improvements in HbA1c (Table 1), patients in both empagliflozin groups had significant reductions in their insulin doses at week 78, and also experienced weight losses versus a small weight gain in those participants receiving placebo.

As in earlier clinical development, empagliflozin was tested in a dose-finding study in Japanese patients with type 2 diabetes [57]. This randomized, placebo-controlled, double-blind study evaluated the efficacy and tolerability of empagliflozin monotherapy (5 mg, 10 mg, 25 mg, and 50 mg once daily) for 12 weeks. All doses of empagliflozin tested led to significant improvements in glycemic control and body weight; improvements in blood pressure were also observed...
Table 1. Summary of Phase II, randomized, controlled trials for empagliflozin – efficacy in patients with type 2 diabetes.

<table>
<thead>
<tr>
<th>Study</th>
<th>Randomized groups (n)</th>
<th>HbA1c (%)</th>
<th>HbA1c (%)</th>
<th>Body weight (kg)</th>
<th>Body weight (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Baseline</td>
<td>Change from baseline</td>
<td>Baseline</td>
<td>Change from baseline</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mean ± SD</td>
<td>Mean (95% CI)</td>
<td>Median (range)</td>
<td>Mean (95% CI)</td>
</tr>
<tr>
<td>Ferrannini et al. [52]</td>
<td>Monotherapy 12 weeks</td>
<td>Empagliflozin 5 mg (81)</td>
<td>7.9 ± 0.8</td>
<td>−0.4 (−0.6, −0.3)</td>
<td>82.8 (51.9–116.0)</td>
</tr>
<tr>
<td></td>
<td>Monotherapy 12 weeks</td>
<td>Empagliflozin 10 mg (81)</td>
<td>8.0 ± 0.8</td>
<td>−0.5 (−0.7, −0.3)</td>
<td>76.8 (45.5–118.0)</td>
</tr>
<tr>
<td></td>
<td>Monotherapy 12 weeks</td>
<td>Empagliflozin 25 mg (82)</td>
<td>7.8 ± 0.8</td>
<td>−0.6 (−0.8, −0.5)</td>
<td>81.2 (49.1–130.0)</td>
</tr>
<tr>
<td></td>
<td>Monotherapy 12 weeks</td>
<td>Open-label metformin (80)</td>
<td>81.0 ± 0.9</td>
<td>−0.7 (−0.9, −0.6)</td>
<td>81.1 (42.0–126.0)</td>
</tr>
<tr>
<td></td>
<td>Monotherapy 12 weeks</td>
<td>Placebo (82)</td>
<td>7.8 ± 0.8</td>
<td>+0.1 (−0.1, +0.3)</td>
<td>82.2 (49.0–152.3)</td>
</tr>
<tr>
<td>Rosenstock et al. [53]</td>
<td>Background metformin 12 weeks</td>
<td>Empagliflozin 1 mg (71)</td>
<td>7.8 ± 0.7</td>
<td>−0.1 (−0.2, +0.1)</td>
<td>90.6 ± 18.9</td>
</tr>
<tr>
<td>Rosenstock et al. [53]</td>
<td>Background metformin 12 weeks</td>
<td>Empagliflozin 5 mg (71)</td>
<td>8.0 ± 0.7</td>
<td>−0.2 (−0.4, −0.1)</td>
<td>87.0 ± 14.8</td>
</tr>
<tr>
<td>Rosenstock et al. [53]</td>
<td>Background metformin 12 weeks</td>
<td>Empagliflozin 10 mg (71)</td>
<td>7.9 ± 0.7</td>
<td>−0.6 (−0.7, −0.4)</td>
<td>87.9 ± 14.4</td>
</tr>
<tr>
<td>Rosenstock et al. [53]</td>
<td>Background metformin 12 weeks</td>
<td>Empagliflozin 25 mg (70)</td>
<td>8.1 ± 0.8</td>
<td>−0.6 (−0.7, −0.4)</td>
<td>90.5 ± 16.9</td>
</tr>
<tr>
<td>Rosenstock et al. [53]</td>
<td>Background metformin 12 weeks</td>
<td>Empagliflozin 50 mg (70)</td>
<td>7.9 ± 0.7</td>
<td>−0.5 (−0.6, −0.3)</td>
<td>91.6 ± 15.8</td>
</tr>
<tr>
<td>Rosenstock et al. [53]</td>
<td>Background metformin 12 weeks</td>
<td>Open-label sitagliptin (71)</td>
<td>8.1 ± 0.9</td>
<td>−0.5 (−0.7, −0.3)</td>
<td>88.0 ± 15.0</td>
</tr>
<tr>
<td>Rosenstock et al. [53]</td>
<td>Background metformin 12 weeks</td>
<td>Placebo (71)</td>
<td>8.0 ± 0.7</td>
<td>+0.2 (−0.0, +0.3)</td>
<td>87.7 ± 15.7</td>
</tr>
<tr>
<td>Kadowaki et al. [57]</td>
<td>Japanese monotherapy 12 weeks</td>
<td>Empagliflozin 5 mg (110)</td>
<td>7.9 ± 0.1</td>
<td>−0.4 ± 0.1</td>
<td>72.3 ± 1.4</td>
</tr>
<tr>
<td>Kadowaki et al. [57]</td>
<td>Japanese monotherapy 12 weeks</td>
<td>Empagliflozin 10 mg (109)</td>
<td>7.9 ± 0.1</td>
<td>−0.4 ± 0.1</td>
<td>68.1 ± 1.4</td>
</tr>
<tr>
<td>Kadowaki et al. [57]</td>
<td>Japanese monotherapy 12 weeks</td>
<td>Empagliflozin 25 mg (109)</td>
<td>7.9 ± 0.1</td>
<td>−0.7 ± 0.1</td>
<td>68.3 ± 1.4</td>
</tr>
<tr>
<td>Kadowaki et al. [57]</td>
<td>Japanese monotherapy 12 weeks</td>
<td>Empagliflozin 50 mg (110)</td>
<td>8.0 ± 0.1</td>
<td>−0.6 ± 0.1</td>
<td>68.2 ± 1.2</td>
</tr>
<tr>
<td>Kadowaki et al. [57]</td>
<td>Japanese monotherapy 12 weeks</td>
<td>Placebo (109)</td>
<td>7.9 ± 0.1</td>
<td>+0.3 ± 0.1</td>
<td>69.0 ± 1.2</td>
</tr>
<tr>
<td>Rosenstock et al. [56]</td>
<td>Add-on to basal insulina 78 weeks</td>
<td>Empagliflozin 10 mg (169)</td>
<td>8.3 ± 0.1</td>
<td>−0.6 ± 0.1</td>
<td>91.6 ± 1.5</td>
</tr>
<tr>
<td>Rosenstock et al. [56]</td>
<td>Add-on to basal insulina 78 weeks</td>
<td>Empagliflozin 25 mg (155)</td>
<td>8.3 ± 0.1</td>
<td>−0.7 ± 0.1</td>
<td>94.7 ± 1.7</td>
</tr>
<tr>
<td>Rosenstock et al. [56]</td>
<td>Add-on to basal insulina 78 weeks</td>
<td>Placebo (170)</td>
<td>8.1 ± 0.1</td>
<td>0.0 ± 0.1</td>
<td>90.5 ± 1.7</td>
</tr>
</tbody>
</table>

CI, confidence interval; SD, standard deviation; SE, standard error.

*Basal insulin dose remained constant for the first 18 weeks, then adjustments were allowed at investigator discretion; the primary endpoint was measured at 18 weeks.

doi: 10.7573/dic.212262.t001
but not statistically assessed for significance. Safety results have not yet been reported in detail, but hypoglycemia was rare, reported in one patient receiving empagliflozin 25 mg and one patient receiving empagliflozin 50 mg, with no events requiring assistance. Adverse events consistent with urinary tract infection or genital infection were reported in less than 1% of patients, and the investigators concluded that based on benefit–risk assessment, 10 mg and 25 mg once daily were appropriate empagliflozin doses for subsequent Phase III trials.

### Beyond Phase II: pivotal trials and post-marketing studies

Phase III trials are often referred to as pivotal, as they provide the evidence for the safety and efficacy of the drug needed to gain its approval for marketing. As with all diabetes therapies, a large program of Phase III trials is required to demonstrate the efficacy and safety of empagliflozin as monotherapy, as initial combination with other agents, or as add-on therapy to stable doses of various other agents. At the time of writing, 12 Phase III trials for empagliflozin are listed on the US National Institutes of Health clinical trials registry (www.clinicaltrials.gov). A number of these have been completed: for some, the study results are reported in the literature (Table 3) and for others preliminary results have been reported, while others are still ongoing (Table 4).

The first of the Phase III studies reported was a randomized, double-blind, active- and placebo-controlled study investigating empagliflozin monotherapy in patients with type 2 diabetes [58]. Participants who had HbA1c values of 7.0–10.0% at screening were randomized to once-daily empagliflozin 10 mg, or 25 mg, once-daily sitagliptin (100 mg), or placebo for 24 weeks. Screened patients with HbA1c >10.0% were not excluded, but were assigned open-label empagliflozin 25 mg. After 24 weeks, placebo-adjusted mean differences in change from baseline were –0.74% (95% CI: –0.88 to –0.59; p <0.0001) for empagliflozin 10 mg, –0.85% (95% CI: –0.99 to –0.71; p <0.0001) for empagliflozin 25 mg, and –0.73% (95% CI: –0.88 to –0.59; p <0.0001) for sitagliptin. In the empagliflozin 25 mg open-label arm, the mean HbA1c fell from 11.5% at baseline to 7.6% at week 24, with a mean change from baseline of –0.74% (95% CI: –0.88 to –0.59; p <0.0001).

---

**Table 2. Safety events of special interest in Phase II, randomized, controlled trials for empagliflozin.**

<table>
<thead>
<tr>
<th>Study</th>
<th>Randomized groups (n)</th>
<th>Hypoglycemia n (%)</th>
<th>Urinary tract infections n (%)</th>
<th>Genital infections n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferrannini et al. [52]  Monotherapy 12 weeks</td>
<td>Empagliflozin 5 mg (81)</td>
<td>0</td>
<td>2 (2.5)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Empagliflozin 10 mg (81)</td>
<td>0</td>
<td>1 (1.2)</td>
<td>3 (3.7)</td>
</tr>
<tr>
<td></td>
<td>Empagliflozin 25 mg (82)</td>
<td>0</td>
<td>1 (1.2)</td>
<td>2 (2.4)</td>
</tr>
<tr>
<td></td>
<td>Open-label metformin (80)</td>
<td>1 (1.2)</td>
<td>2 (2.5)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Placebo (82)</td>
<td>1 (1.2)</td>
<td>1 (1.2)</td>
<td>0</td>
</tr>
<tr>
<td>Rosenstock et al. [53]  Background metformin 12 weeks</td>
<td>Empagliflozin 1 mg (71)</td>
<td>0</td>
<td>2 (2.8)</td>
<td>1 (1.4)</td>
</tr>
<tr>
<td></td>
<td>Empagliflozin 5 mg (71)</td>
<td>3 (4.2)</td>
<td>2 (2.8)</td>
<td>4 (5.6)</td>
</tr>
<tr>
<td></td>
<td>Empagliflozin 10 mg (71)</td>
<td>0</td>
<td>3 (4.2)</td>
<td>7 (9.9)</td>
</tr>
<tr>
<td></td>
<td>Empagliflozin 25 mg (70)</td>
<td>0</td>
<td>4 (5.7)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Empagliflozin 50 mg (70)</td>
<td>1 (1.4)</td>
<td>3 (4.3)</td>
<td>2 (2.9)</td>
</tr>
<tr>
<td></td>
<td>Open-label sitagliptin (71)</td>
<td>2 (2.8)</td>
<td>3 (4.2)</td>
<td>2 (2.8)</td>
</tr>
<tr>
<td></td>
<td>Placebo (71)</td>
<td>0</td>
<td>2 (2.8)</td>
<td>0</td>
</tr>
<tr>
<td>Kadowaki et al. [57]  Japanese monotherapy 12 weeks</td>
<td>Empagliflozin 5 mg (110)</td>
<td>0</td>
<td>0</td>
<td>1 (0.9)</td>
</tr>
<tr>
<td></td>
<td>Empagliflozin 10 mg (109)</td>
<td>0</td>
<td>1 (0.9)</td>
<td>1 (0.9)</td>
</tr>
<tr>
<td></td>
<td>Empagliflozin 25 mg (109)</td>
<td>1 (0.9)</td>
<td>1 (0.9)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Empagliflozin 50 mg (110)</td>
<td>1 (0.9)</td>
<td>1 (0.9)</td>
<td>1 (0.9)</td>
</tr>
<tr>
<td></td>
<td>Placebo (109)</td>
<td>0</td>
<td>1 (0.9)</td>
<td>0</td>
</tr>
<tr>
<td>Rosenstock et al. [56]  Add-on to basal insulina 78 weeks</td>
<td>Empagliflozin 10 mg (169)</td>
<td>36.1%</td>
<td>14.8%</td>
<td>7.7%</td>
</tr>
<tr>
<td></td>
<td>Empagliflozin 25 mg (155)</td>
<td>36.1%</td>
<td>11.6%</td>
<td>5.2%</td>
</tr>
<tr>
<td></td>
<td>Placebo (170)</td>
<td>35.3%</td>
<td>8.8%</td>
<td>1.8%</td>
</tr>
</tbody>
</table>

*Basal insulin dose remained constant for the first 18 weeks, then adjustments were allowed at investigator discretion; the primary endpoint was measured at 18 weeks.

**doi:** 10.7573/dic.212262.t002
of –3.7% (95% CI: –4.1 to –3.3%), and, among randomized patients with baseline HbA1c <8.5%, improvements in glycemic control were comparable between empagliflozin and sitagliptin groups; however, among patients with baseline HbA1c >8.5%, both empagliflozin doses elicited greater HbA1c improvements when compared with sitagliptin. Adjusted mean changes from baseline in HbA1c were –1.04% (95% CI: –1.25 to –0.83) with sitagliptin compared with adjusted mean changes with empagliflozin 10 mg of –1.44% (95% CI: –1.64 to –1.23; p=0.0077 versus sitagliptin) and with empagliflozin

### Table 3. Results in empagliflozin Phase III clinical trials.

<table>
<thead>
<tr>
<th>Patients Background therapy Planned enrollment (n)</th>
<th>Study duration</th>
<th>Treatment arms</th>
<th>Primary endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Monotherapy</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01177813 [58]</td>
<td>24 weeks</td>
<td>Empagliflozin 10 mg qd</td>
<td>Change from baseline in HbA1c, mean (95% CI)</td>
</tr>
<tr>
<td>Adults with type 2 diabetes Drug naïve n=986</td>
<td></td>
<td>Empagliflozin 25 mg qd</td>
<td>–0.66% (–0.76, –0.56)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sitagliptin 100 mg qd</td>
<td>–0.78% (–0.88, –0.67)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Placebo</td>
<td>–0.66% (–0.76, –0.56)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Open-label empagliflozin 25 mg qd</td>
<td>+0.08% (–0.03, +0.18)</td>
</tr>
</tbody>
</table>

| **Add-on therapy**                                  |                |                |                  |
| NCT01210001 [62]                                   | 24 weeks       | Empagliflozin 10 mg qd | Change from baseline in HbA1c, mean ± SE |
| Adults with type 2 diabetes Pioglitazone ± metformin n=499 |                | Empagliflozin 25 mg qd | –0.59 ± 0.07% |
|                                                      |                | Placebo          | –0.72 ± 0.07% |
|                                                      |                | Open-label empagliflozin 25 mg qd | –0.11 ± 0.07% |

| NCT01159600-met [60]                                | 24 weeks       | Empagliflozin 10 mg qd |                  |
| Adults with type 2 diabetes Metformin n=637         |                | Empagliflozin 25 mg qd |                  |
|                                                      |                | Placebo          |                  |
|                                                      |                | Open-label empagliflozin 25 mg qd | –0.70 ± 0.05% |
|                                                      |                |                  | –0.77 ± 0.05% |
|                                                      |                |                  | –0.13 ± 0.05% |
|                                                      |                |                  | –3.23 ± 0.22% |

| NCT01159600 [61]                                   | 24 weeks       | Empagliflozin 10 mg qd |                  |
| Adults with type 2 diabetes Metformin + sulfonylurea n=669 |                | Empagliflozin 25 mg qd |                  |
|                                                      |                | Placebo          |                  |
|                                                      |                | Open-label empagliflozin 25 mg qd | –0.82 ± 0.05% |
|                                                      |                |                  | –0.77 ± 0.05% |
|                                                      |                |                  | –0.17 ± 0.05% |
|                                                      |                |                  | –2.89 ± 0.16% |

| **Special populations**                            |                |                  |                  |
| NCT01370005 [64]                                   | 12 weeks       | Empagliflozin 10 mg qd | Co-primary endpoints: change from baseline in HbA1c, mean ± SE and 24-hour SBP, mean ± SE |
| Adults with type 2 diabetes & hypertension n=825   |                | Empagliflozin 25 mg qd |                  |
|                                                      |                | Placebo          |                  |
|                                                      |                |                  | HbA1c: –0.59 ± 0.04 |
|                                                      |                |                  | 24-hour SBP: –2.95 ± 0.48 |
|                                                      |                |                  | HbA1c: –0.62 ± 0.04 |
|                                                      |                |                  | 24-hour SBP: –3.68 ± 0.48 |
|                                                      |                |                  | HbA1c: +0.03 ± 0.04 |
|                                                      |                |                  | 24-hour SBP: +0.48 ± 0.49 |

| NCT01164501 [63]                                   | 52 weeks       | Patients with stage 2 CKD: |                  |
| Adults with type 2 diabetes & renal impairment* n=741 | (primary endpoint after 24 weeks) | Empagliflozin 10 mg qd | Change from baseline in HbA1c, mean (95% CI) |
|                                                      |                | Empagliflozin 25 mg qd |                  |
|                                                      |                | Placebo          |                  |
|                                                      |                | Patients with stage 3 CKD: |                  |
|                                                      |                | Empagliflozin 25 mg qd |                  |
|                                                      |                | Placebo          |                  |
|                                                      |                |                  | –0.46% (–0.60, –0.32) |
|                                                      |                |                  | –0.63% (–0.77, –0.49) |
|                                                      |                |                  | +0.06% (–0.08, +0.20) |
|                                                      |                |                  | –0.37 (–0.47, –0.27) |
|                                                      |                |                  | +0.05 (–0.05, +0.15) |

| qd, once daily; SBP, systolic blood pressure.       |                |                  |                  |
| *In patients with screening HbA1c >11%.            |                |                  |                  |
| *Estimated glomerular filtration rate (eGFR) of <90 mL/min, as determined during screening and the run-in phase, using the Modification of Diet in Renal Disease (MDRD) equation, patients with eGFR <15 mL/min were excluded. | | | | | doi: 10.7573/dic.212262.t003 |
Table 4. Empagliflozin Phase III clinical trials in progress.

<table>
<thead>
<tr>
<th>Patients</th>
<th>Study duration</th>
<th>Treatment arms</th>
<th>Primary endpoint (planned)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Add-on therapy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01167881 [67]</td>
<td>104 weeks &amp; 104-week extension</td>
<td>Empagliflozin 25 mg qd Glimepiride 1–4 mg</td>
<td>HbA1c</td>
</tr>
<tr>
<td>Adults with type 2 diabetes Metformin n=1549</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Combination regimens</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01719003</td>
<td>24 weeks</td>
<td>Empagliflozin 10 mg qd Empagliflozin 25 mg qd Empagliflozin 10 mg divided dose + metformin 500 mg bid Empagliflozin 10 mg divided dose + metformin 1000 mg bid Empagliflozin 25 mg divided dose + metformin 500 mg bid Empagliflozin 25 mg divided dose + metformin 1000 mg bid Metformin 500 mg bid Metformin 1000 mg bid Open-label empagliflozin 25 mg divided doses + metformin 1000 mg bid</td>
<td>HbA1c</td>
</tr>
<tr>
<td>Adults with type 2 diabetes Drug naïve n=1364</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01734785</td>
<td>24 weeks</td>
<td>Empagliflozin 10 mg + linagliptin 5 mg FDC qd Empagliflozin 25 mg + linagliptin 5 mg FDC qd Linagliptin 5 mg qd</td>
<td>HbA1c</td>
</tr>
<tr>
<td>Adults with type 2 diabetes Drug naïve or metformin n=444</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01422876</td>
<td>52 weeks</td>
<td>Empagliflozin 25 mg + linagliptin 5 mg FDC qd Empagliflozin 10 mg + linagliptin 5 mg FDC qd Empagliflozin 25 mg qd Empagliflozin 10 mg qd Linagliptin 5 mg qd</td>
<td>HbA1c</td>
</tr>
<tr>
<td>Adults with type 2 diabetes Drug naïve or metformin n=1406</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01778049</td>
<td>24 weeks</td>
<td>Empagliflozin 10 mg + linagliptin 5 mg FDC qd Empagliflozin 25 mg + linagliptin 5 mg FDC qd Empagliflozin 10 mg + placebo FDC qd Empagliflozin 25 mg + placebo FDC qd</td>
<td>HbA1c</td>
</tr>
<tr>
<td>Adults with type 2 diabetes Metformin n=690</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Special populations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01306214</td>
<td>52 weeks (primary endpoint after 18 weeks)</td>
<td>Empagliflozin 10 mg qd Empagliflozin 25 mg qd Placebo</td>
<td>HbA1c</td>
</tr>
<tr>
<td>Adults with type 2 diabetes &amp; obesity Insulin ± metformin n=566</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethnic/Racial groups</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01947855</td>
<td>4 weeks</td>
<td>Empagliflozin 10 mg qd Empagliflozin 25 mg qd Placebo</td>
<td>PPG</td>
</tr>
<tr>
<td>Japanese adults with type 2 diabetes Drug naïve or 1 OAD n=60</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01368081</td>
<td>52 weeks</td>
<td>Empagliflozin 10 mg qd Empagliflozin 25 mg qd Metformin</td>
<td>Safety</td>
</tr>
<tr>
<td>Japanese adults with type 2 diabetes 1 OAD n=1162</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
25 mg of –1.43% (95% CI: –1.65 to –1.21; p=0.0119 versus sitagliptin). Empagliflozin also mediated clinically relevant reductions in weight, waist circumference, and blood pressure compared with either placebo or sitagliptin. Furthermore, both empagliflozin doses were well tolerated with no increased risk of hypoglycemia versus placebo or sitagliptin. Adverse events consistent with urinary tract infection occurred at similar rates across the groups, but when analyzed separately, were reported more frequently in female patients treated with empagliflozin compared with those treated with placebo or sitagliptin. Events consistent with genital infection were more frequently reported with empagliflozin, although all events were considered mild.

One of the key hypothetical advantages of SGLT2 inhibitors such as empagliflozin is the ability to use them in combination with any of the current treatment options for glycemic control, since the mechanism of action is independent of insulin and should complement all other currently available agents [59]. To investigate this, additional Phase III trials have investigated empagliflozin as an add-on therapy to other glucose-lowering treatments for 24 weeks. Empagliflozin as add-on to metformin improved glycemic control, as well as inducing significant reductions in body weight and blood pressure [60]. At 24 weeks, HbA1c was improved by a placebo-corrected mean of –0.57% (95% CI: –0.70 to –0.43) with empagliflozin 10 mg and –0.64% (95% CI: –0.77 to –0.50) with empagliflozin 25 mg; both p<0.001 vs placebo. This combination of agents was also well tolerated, with a low risk of hypoglycemia [60]. When empagliflozin was investigated as an add-on therapy to metformin and sulfonylurea, and to pioglitazone with or without metformin, similar results in terms of improvements in glycemic control, body weight, and blood pressure were demonstrated (Table 3) [61,62]. Empagliflozin was also well tolerated in these studies, although there was a higher incidence of hypoglycemia with empagliflozin in combination with metformin and sulfonylurea [61,62].

Results have also been reported for studies in patients with type 2 diabetes and renal impairment [63], and for patients with hypertension [64]. In the study of patients with type 2 diabetes and renal impairment, patients with CKD stage 2 (that is, mild renal impairment with eGFR ≥60 to <90 mL/min/1.73 m²) or CKD stage 3 (moderate renal impairment with eGFR ≥30 to <60 mL/min/1.73 m²) were randomized to empagliflozin or placebo as add-on to existing therapy for 52 weeks [63]. By design, patients with mild renal impairment could receive empagliflozin 10 mg or 25 mg, while those with moderate renal impairment received 25 mg. Empagliflozin was well tolerated in these patients; small decreases in eGFR were observed, which reversed within 3 weeks after the end of treatment, indicating this effect is due to hemodynamic changes associated with SGLT2 inhibition [63]. The primary efficacy endpoint was the change to week 24 and, compared with placebo, empagliflozin significantly reduced HbA1c in both groups. In the group with stage 2 CKD, the adjusted mean changes from baseline in HbA1c versus placebo at week 24 were –0.52% (95% CI: –0.72 to –0.32) for empagliflozin 10 mg and –0.68% (95% CI: –0.88 to –0.49) for empagliflozin 25 mg (both p<0.0001), while in patients with stage 3 CKD, it was –0.42% (95% CI: –0.56 to –0.28) for empagliflozin 25 mg (p<0.0001); these reductions were sustained to 52 weeks. Both groups of patients also had

<table>
<thead>
<tr>
<th>Patients</th>
<th>Study duration</th>
<th>Treatment arms</th>
<th>Primary endpoint (planned)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adults with type 2 diabetes &amp; increased cardiovascular risk (EMPA-REG OUTCOMETM) n=7000</td>
<td>Endpoint driven – expected ~5 years</td>
<td>Empagliflozin 10 mg qd</td>
<td>CV death, non-fatal MI or non-fatal stroke*</td>
</tr>
<tr>
<td>Adults with type 2 diabetes &amp; increased cardiovascular risk (EMPA-REG OUTCOMETM) n=7000</td>
<td>76 weeks total (52-week extension to 24-week trials)</td>
<td>Patients continue previous treatment as randomized in 24-week trials</td>
<td>Safety</td>
</tr>
<tr>
<td>Adults with type 2 diabetes &amp; increased cardiovascular risk (EMPA-REG OUTCOMETM) n=7000</td>
<td>76 weeks total (52-week extension to 24-week trials)</td>
<td>Empagliflozin 25 mg qd</td>
<td>Safety</td>
</tr>
<tr>
<td>Adults with type 2 diabetes &amp; increased cardiovascular risk (EMPA-REG OUTCOMETM) n=7000</td>
<td>76 weeks total (52-week extension to 24-week trials)</td>
<td>Placebo (usual care)</td>
<td>Safety</td>
</tr>
</tbody>
</table>

bid, twice daily; CV, cardiovascular; FDC, fixed-dose combination; MI, myocardial infarction; OAD, oral antidiabetes drug; PPG, post-prandial glucose; qd, once daily.

*First occurrence of any of the following adjudicated components of the primary composite endpoint: CV death (including fatal stroke and fatal MI), non-fatal MI and non-fatal stroke.

Based on a search of the US National Institutes of Health clinical trial registry, for trials of empagliflozin and Phase III (including completed, ongoing and planned studies) conducted October 17, 2013; studies with published results were not included.

doi: 10.7573/dic.212262.t004
improvement in FPG, body weight, and blood pressure at week 24. While attenuated efficacy of SGLT2 inhibitors is expected in patients with renal impairment, these results suggest patients with mild or moderate renal impairment could achieve clinically significant improvements with empagliflozin, as has also been seen with canagliflozin [65]. However, conflicting results have been seen with dapagliflozin, where reductions in HbA1c, which did not meet statistical significance in patients with moderate renal impairment (eGFR 30–59 mL/min/1.73 m²) [66].

In the second study, patients with type 2 diabetes and hypertension (mean seated systolic blood pressure 130–159 mmHg and diastolic blood pressure 80–99 mmHg) were randomized to empagliflozin 10 mg, 25 mg, or placebo for 12 weeks [64]. Preliminary results have been reported, and both empagliflozin doses were associated with significant improvements in HbA1c and systolic blood pressure after 12 weeks, with 18% of the empagliflozin 25-mg group and 16% of the 10-mg group meeting blood pressure control targets, versus 8% of the placebo group [64].

Other Phase III trials of empagliflozin are still in the planned stages or ongoing, but include fixed-dose combination regimens, and trials in Japanese patients. A head-to-head trial comparing empagliflozin 25 mg with glimepiride 1–4 mg, both as add-on to background metformin, is also under way and should provide valuable information for the common clinical decision of the optimal second-line therapy to add to metformin [67]. An ongoing multicenter, randomized, double-blind, placebo-controlled cardiovascular outcome event trial (EMPA-REG OUTCOME™, registered as NCT01131676) with empagliflozin was designed to assess the effect of empagliflozin (10 mg or 25 mg) compared with usual care on cardiovascular events. The investigators plan to recruit more than 7000 patients with type 2 diabetes with an elevated cardiovascular risk and the trial is designed to test firstly for cardiovascular safety. If safety is demonstrated in this cardiovascular outcomes study, the trial is powered to test for a reduced risk of cardiovascular events (that is, superiority) with empagliflozin [68]. In addition to the clinical trial program, post-marketing safety assessments will be an essential part of confirming long-term safety in clinical practice, and such studies have been required for the previously approved SGLT2 inhibitors, canagliflozin and dapagliflozin [69,70]. For empagliflozin, information is not yet available, but assuming they are undertaken, post-marketing pharmacovigilance studies with empagliflozin could not only assess long-term safety but would additionally be useful in assessing the risk of potential adverse events noted with other agents within this therapeutic class.

Beyond type 2 diabetes?

Due to the mechanism of action of SGLT2 inhibitors, they have pharmacologic consequences in addition to glucose lowering that could translate into beneficial effects in patients with type 2 diabetes [13]. The increased UGE leads not only to reduced blood sugar and to weight loss, but potentially also to reductions in blood pressure, which at least in part could be mediated via osmotic diuresis [13]. While these agents may lend themselves to treatment in patients with hypertension or obesity, as yet, no trials have been registered for empagliflozin as a treatment for either condition, in patients without type 2 diabetes.

However, SGLT2 inhibitors are unique among oral antidiabetes drugs in that they are not dependent on endogenous insulin, making treatment of patients with type 1 diabetes a possibility [19]; and there have been some early trials in this area. In streptozotocin-induced rat models of type 1 diabetes, empagliflozin in combination with 1.5 IU insulin induced a similar glucose-lowering effect to 6 IU insulin, suggesting empagliflozin could be a useful option to allow dose reduction of insulin [71]. A pilot study in patients with type 1 diabetes enrolled 42 patients in an 8-week, single-arm, open-label, Phase II study of empagliflozin 25 mg once daily as adjunctive therapy to insulin [72]. In this short-term study, empagliflozin was associated with improvement in glycemic control, a reduction in rates of hypoglycemia, a substantial reduction in insulin requirement and body weight, and was generally well tolerated, suggesting it may have potential in these patients. However, as the primary endpoint of the study, the investigators assessed glomerular filtration rate and effective renal plasma flow under clamped euglycemic conditions (4–6 mmol/L) and hyperglycemic conditions (9–11 mmol/L) at baseline and again after 8 weeks of empagliflozin treatment, and compared results for patients with hyperfiltration (GFR ≥135 mL/min/1.73 m²; n=27) or normal GFR (n=13) [73]. In the patients with hyperfiltration, empagliflozin attenuated hyperfiltration under euglycemic and hyperglycemic conditions. This was accompanied by declines in plasma nitric oxide levels and effective renal plasma flow and an increase in renal vascular resistance. In the patients with normal GFR, empagliflozin did not affect GFR, other renal function parameters, or plasma nitric oxide levels [73]. These results support further evaluation of empagliflozin in type 1 diabetes, with a potential role in reducing the risk of diabetic nephropathy via reducing renal hyperfiltration.

**Potential role of empagliflozin in the treatment of diabetes**

The clinical development of SGLT2 inhibitors represents an interesting and important addition to the range of treatments currently available to manage hyperglycemia. Of note, these oral agents provide an insulin-independent mechanism to reduce hyperglycemia through inhibition of SGLT2 and excretion of excess glucose by the urine. Pharmacokinetic studies of empagliflozin have shown that it is rapidly absorbed following oral administration, reaching maximal plasma concentrations within 1–3 hours. Early studies also have demonstrated that once-daily administration of empagliflozin in patients with type 2 diabetes is well tolerated.
and results in improved glycemic control, with a lack of drug–
drug interactions seen when taken with other commonly
administered medications. Phase II and III trials have also shown
that empagliflozin, as monotherapy or add-on to other glucose-
lowering treatments, led to improved glycemic control, with the
largest reductions seen in those with the highest HbA1c levels
at baseline. Empagliflozin was generally well tolerated, with few
patients discontinuing therapy due to AEs, despite an increased
incidence of genital infections. Importantly, there was no
increased risk of hypoglycemia versus placebo, which could be
a key consideration for many patients, as could the reductions
in body weight and blood pressure, suggesting empagliflozin
could be a useful option in many patients.

In the USA, empagliflozin may well be approved for glycemic
control in patients with type 2 diabetes, both as monotherapy
and in combination with other agents, as was the case for
canagliflozin and dapagliflozin [74,75]. Since the drug class is so
newly available, expert groups will likely recommend use with
cautions initially [76], and data from the overall empagliflozin
clinical trial program will need to be collated to determine if the
drug has any specific properties that may distinguish its use
over other members of the SGLT2 class. However, when
further experience is gained, this drug class has the potential
to be widely used since it offers the obvious advantages of oral
combination of metformin, a DPP-4 inhibitor and an SGLT2
inhibitor is especially appealing, since it would not be expected
to result in weight gain or hypoglycemia. It is too early to
determine whether animal studies suggesting preservation of
islet function/mass and improved insulin action may be expected
and DPP-4 inhibitors. The insulin-independent mechanism
of action of empagliflozin suggests it will complement these
options, and this appears to be borne out by the results reported
to date. Therefore, we may expect that empagliflozin will
also be used as a component of triple combination regimens
with many of these agents, as recommended for patients not
achieving therapeutic targets on dual therapy [36]. In clinical
trials, patients whose blood glucose was not controlled on
dual therapy were significantly more likely to achieve goal with
addition of empagliflozin; however, where very large reductions
in HbA1c are still required despite dual therapy, it may be more
appropriate to consider insulin. For patients on insulin, addition
of empagliflozin may be considered as an adjunctive agent,
not only because of the expected improvements in HbA1c
and weight, but also as a potential alternative to up-titration of
insulin, and clinical trials have shown patients can even achieve
significant reductions in their insulin doses with long-term
empagliflozin add-on to insulin.

The number of agents on the market allows combination
therapy to be individualized to each patient’s needs, although
the combination of metformin, a DPP-4 inhibitor and an SGLT2
inhibitor is especially appealing, since it would not be expected
to result in weight gain or hypoglycemia. It is too early to
determine whether animal studies suggesting preservation of
islet function/mass and improved insulin action will translate
into clinical effects, although these suggest that empagliflozin
should have sustained benefit over the long term, and may also
have a role in early treatment of recently diagnosed patients.

Contributions
The author was fully responsible for all content and
editorial decisions, was involved at all stages of manuscript
development, and has approved the final version of the review
that reflects the author’s interpretation and conclusions.

Potential conflicts of interest
The International Committee of Medical Journal Editors’
(ICMJE) Potential Conflicts of Interests form for the author
is summarized below. The original form is available for
download at: http://www.drugsincontext.com/wp-content/
uploads/2014/07/dic.212262-COI.pdf

JN reports receiving consultancy/speakers bureau fees from
Janssen Pharmaceuticals and Sanofi. His institution has
received grant support from Amylin, Johnson & Johnson, Merck,
AstraZeneca, and Novo Nordisk.

Acknowledgements
Medical writing assistance, supported financially by Boehringer
Ingelheim, was provided by Geraldine Thompson of Envision
Scientific Solutions during the preparation of this review.
Boehringer Ingelheim was given the opportunity to check the
data used in the manuscript for factual accuracy only.
References


46. Ring A, Brand T, Macha S et al. The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong
http://dx.doi.org/10.1186/1475-2840-12-70

http://dx.doi.org/10.1007/s13300-013-0030-2

http://dx.doi.org/10.1111/dom.12073

http://dx.doi.org/10.1111/jdi.12110

http://dx.doi.org/10.1111/dom.12182

http://dx.doi.org/10.1111/dom.12183

http://dx.doi.org/10.1111/dom.12081

http://dx.doi.org/10.1111/dom.12185


http://dx.doi.org/10.2337/dc13-0663

http://dx.doi.org/10.1016/j.jcjd.2013.08.093


http://dx.doi.org/10.1016/S2213-8587(13)70084-6

http://dx.doi.org/10.2147/DMSO.S22545

http://dx.doi.org/10.2337/dc13-2105

http://dx.doi.org/10.2337/dc12-2673

http://dx.doi.org/10.2337/dc12-2673

http://dx.doi.org/10.1111/dom.12188.

http://dx.doi.org/10.1111/dom.12090


